Table 5.
Therapy | Injection-Site Reaction | Flu-like Symptoms | Dyspigmentation | Bullae/Vesicles | Desquamation |
---|---|---|---|---|---|
MMR (n = 24) | 92% (N = 22) | 46% (N = 11) | 4% (N = 1) | — | — |
PPD (n = 19) | 90% (N = 18) | 35% (N = 7) | 25% (N = 5) | 20% (N = 4) | 5% (N = 1) |
Vitamin D3 (n = 15) | 93% (N = 14) | — | 20% (N = 3) | 7% (N = 1) | — |
Candida (n = 14) | 93% (N = 13) | 79% (N = 11) | 7% (N = 1) | 14% (N = 2) | 7% (N = 1) |
Abbreviations: MMR, measles, mumps, rubella vaccine; PPD, purified protein derivative.
n = number of studies including each respective therapy that reported any adverse effects. N = number of studies reporting that specific adverse effect. The number of studies reporting specific adverse effects for each of the most common therapies is shown.